Bridging the gap in pediatric cancer rehabilitation care: a multi-perspective survey study - Takeaways - MDSpire

Bridging the gap in pediatric cancer rehabilitation care: a multi-perspective survey study

  • By

  • Filip Jevič

  • Anna Vašinová

  • Aleš Rak

  • Andrea Kašparová

  • Marie Ohnisková

  • Adelaida Dizonová

  • Kristýna Pospíšilová

  • July 7, 2026

  • 0 min

Share

  • 1

    Rehabilitation is essential in pediatric oncology, yet 10.4% of children did not receive needed rehabilitation during treatment.

  • 2

    The unmet need for rehabilitation increased to 13.3% after treatment completion, particularly among lymphoma and spinal cord tumor patients.

  • 3

    A significant education gap exists, with 80% of physiotherapists and 74% of rehabilitation physicians feeling inadequately trained.

  • 4

    Qualitative analysis identified barriers such as informational deficits, insufficient infrastructure, and professional uncertainty.

  • 5

    66% of physiotherapists and 54% of physicians expressed interest in joining a specialized competence network to improve rehabilitation access.

Original Source(s)

Bridging the gap in pediatric cancer rehabilitation care: a multi-perspective survey study

  • by Filip Jevič, Anna Vašinová, Aleš Rak, Andrea Kašparová, Marie Ohnisková, Adelaida Dizonová, Kristýna Pospíšilová

  • July 7, 2026

Related Content

Baptist Health Cancer Care to Present Research on Precision Radiation Therapy Across Complex Cancers at ASTRO 2026

Experts across Baptist Health Herbert Wertheim Cancer Institute and Eugene M. & Christine E. Lynn Cancer Institute will present new radiation oncology research and clinical expertise at the 2026 Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 26-30, 2026, in Boston.

  • by

  • July 7, 2026

  • 8 min
Efficacy and safety of acupuncture for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trial

Predictive value of Ki-67 expression in predicting pathological response to neoadjuvant chemotherapy combined with immunotherapy in lung squamous cell carcinoma